1. Articles from businesswire.com

  2. 1-22 of 22
    1. YmAbs Raises $50 Million in Equity Financing

      NEW YORK--(BUSINESS WIRE)--Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that it has closed a private placement among HBM Healthcare Investments and its current shareholders, raising $50 million. YmAbs’ Founder, President and Head of Business Development and Strategy, Thomas Gad said, “We are very pleased to welcome HBM as a significant shareholder in YmAbs, together with our existing shareh

      Read Full Article
      Mentions: Immunotherapy
    2. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    3. YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      "Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced positive top line results from a pivotal study of 131I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 months average survival for the patients treated with 131I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have ...

      Read Full Article
    4. BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403

      LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent International (BINV) and Oncurious NV today announce that the companies have signed a partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). Accessing the NMRTC network of specialist clinicians will serve to accelerate the enrollment of patients to the planned phase I/IIa trial of TB-403 in pediatric patients with rare but life threatening cancers; medulloblastoma, neuroblastoma, and Ewing’s sar

      Read Full Article
      Mentions: NMTRC
    5. Pediatrics Data Platform Announced at White House Precision Medicine Initiative

      “The ‘big data’ genomics revolution presents us with unprecedented opportunities to improve treatments for pediatric brain tumors, which are the leading cause of disease-related death in children,” said Phillip Storm, M.D., division chief of Neurosurgery at CHOP and the Center’s co-director.  CHOP’s commitment to PMI is the product of collaborative efforts in pediatric cancer research that include a national network of more than 15 leading hospitals, numerous industry partners, foundations, patients and their families. The Cavatica system is central to these efforts, integrating a cloud-based, open infrastructure with big data analytics so that researchers can leverage a ...

      Read Full Article
      Mentions: Genetics
    6. Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE™ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers

      “One of the biggest impediments to progress in the field of childhood cancer is the paucity of genomic data available from patients at the time of disease relapse. These data are critical to defining comprehensive strategies to precisely treat relapsed disease, and more importantly, to prevent disease recurrence in the first place,” stated John M. Maris, M.D., Giulio D'Angio Endowed Professor of Pediatric Oncology at Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania. “The data being made available from Foundation Medicine will serve as a tremendous resource for the cancer research ...

      Read Full Article
    7. FDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant

      "Following an allogeneic transplant, a lack of sufficient mature T cells constitutes immune deficiency that can contribute to infections, viral reactivation, and relapse. The ability to correct this immune deficiency through the add-back of mature donor T cells, without raising the risk of uncontrollable GvHD, has the potential to fundamentally change the risk profile of allogeneic transplantation.

      “Expanding the availability of hematopoietic stem cell transplants to more patients with rare genetic diseases and blood cancers is a primary goal of our BPX-501 program,” commented Tom Farrell, President and CEO of Bellicum Pharmaceuticals. “The FDA’s approval of our request for ...

      Read Full Article
    8. Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children

      PHOENIX--(BUSINESS WIRE)--In a press conference today, Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. With leadership at Phoenix Children’s Hospital helping to initiate this consortium, all founding partners will seek to apply the most comprehensive cancer

      Read Full Article
      Mentions: Immunotherapy
    9. Ignyta Announces Initiation of STARTRK “Next Generation” Phase 1/1b Pediatric Clinical Trial of Entrectinib

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the initiation of STARTRK-NG, a new pediatric Phase 1/1b clinical trial of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK. STARTRK-NG (which stands for “Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation”) is a multicenter, open

      Read Full Article
      Mentions: ALK
    10. New Test Shows Effectiveness of Cancer Therapy in Children

      "An important benefit of CEUS imaging is that it allows us to quantify blood flow and determine if tumors are responding to the blood vessel targeting chemotherapy, whereas the conventional method of assessing these tumors with CT and MR evaluates only changes in tumor size. The St Jude investigators found that CEUS measurements predicted which patients would respond to therapy at very early time points. The results were announced today at the annual International Contrast Ultrasound Society (ICUS) conference in Chicago."

      Read Full Article
      Mentions: Imaging
    11. RCT Demonstrates a Hundred-Fold Improvement in Penetration of Solid Tumors Using Therapeutic ABDURINS Compared to Antibodies

      TUCSON, Ariz.--(BUSINESS WIRE)--Research Corporation Technologies (RCT) and collaborators have demonstrated that the small size and long half-life of ABDURIN binders targeting EphA2 on cancer cells leads to a 50- to 150-fold increase in penetration and accumulation into tumors compared to antibodies binding the same target. The PLoS ONE paper reports the engineering of large and diverse ABDURIN libraries and the use of phage and DNA display to isolate specific, high affinity ABDURINS that bind

      Read Full Article
      Mentions: Antibody
    12. Admune Announces the First-in-Human Study of Heterodimeric IL-15 (hetIL-15) with Broad Applications for Cancer Immunotherapy

      "Admune Therapeutics, a clinical-stage biotechnology company developing cytokine drugs for cancer immunotherapy, announced today that enrollment has initiated in a Phase I clinical trial evaluating the safety and efficacy of its lead compound hetIL-15 (IL15:IL15Ra). Prior studies indicate hetIL-15expands and activates relevant populations of lymphocytes, the white blood cells involved in immune system regulation. The trial will be conducted through the National Cancer Institute at the National Institutes of Health."

      Read Full Article
    13. Childhood Cancer Advocates Take Capitol Hill

      Childhood Cancer Advocates Take Capitol Hill

      "More than 300 cancer advocates from across the US - including more than 35 kids who are survivors - are hitting Capitol Hill on Monday and Tuesday to call on Congress to provide more funding for research and to pass the Childhood Cancer STAR ACT. June 15 and 16 mark the fourth annual Childhood Cancer Action Days coordinated by the Alliance for Childhood Cancer."

      Read Full Article
      Mentions: Treatment
    14. Principia Biopharma and UCSF Scientists Announce Publication of Seminal Paper on Reversible Covalent Drugs in Nature Chemical Biology

      )--Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, today announced the publication of a seminal paper establishing a new category of oral small molecule drugs, which are able to form reversible covalent bonds with antibody-like specificity.

      Read Full Article
      Mentions: Antibody
    15. Children’s Hospital Los Angeles Researchers Find How the Tumor Microenvironment Contributes to Drug-Resistant Neuroblastoma

      Children’s Hospital Los Angeles Researchers Find How the Tumor Microenvironment Contributes to Drug-Resistant Neuroblastoma

      "The scientists found that specific miRNAs were exchanged (via exosome “envelopes”) between the tumor and TAMs, and discovered the process by which cancer cells release these envelopes and TAMs receive them. As a result of the exchange, a specific microRNA called MiR155, which is seen at high levels in tumors, is up regulated. Yet, when the researchers looked for expression of MiR155 in cancer cell lines, it was surprisingly low. It turns out this is because MiR155 doesn’t derive from the cancer cell line, but from the tumor microenvironment, and is secreted by the exosome back to the cancer ...

      Read Full Article
    16. New Data Demonstrate Potential of Biothera’s Investigational Cancer Immunotherapy to Re-Orient the Tumor Microenvironment to Facilitate Greater Anti-Tumor Activity

      "PAMPs are naturally recognized by the innate immune system (neutrophils, monocytes, macrophages, dendritic cells) and elicit a coordinated immune response to an invading pathogen involving both innate and adaptive immune cells. As a PAMP, Imprime PGG also effectively evokes a coordinated immune response, binding to and priming innate immune effector cells to recognize and kill antibody-targeted cancer cells. This binding enables critical cross-talk between the innate immune effector cells and the adaptive immune system that drives cytotoxic T cell expansion and the production of anti-tumor cytokines."

      Read Full Article
      Mentions: Immunotherapy
    17. MaxCyte and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies

      "MaxCyte’s unique approach to CAR cell therapy allows targeting of solid tumor cancers by enabling control over the on-target, off-tumor toxicity, which limits other CAR therapies to hematological cancers. MaxCyte achieves this by introducing the CAR construct as a transiently expressing messenger RNA (mRNA), thus allowing control of the duration of expression and toxicity against target antigens in normal tissue. This unique approach also avoids the cell expansion step required for standard approaches, dramatically reducing manufacturing time and expense for CAR therapies from days or weeks to a matter of hours."

      Read Full Article
    18. Acetylon Announces Preclinical Anti-cancer Activity of Selective HDAC1/2 Inhibitors in Neuroblastoma and Acute Myeloid Leukemia

      "In particular, HDAC1/2 inhibition has recently been shown in the literature to induce a favorable gene expression pattern similar to that driven by retinoic acid in neuroblastoma cells. Retinoids are chemicals related to vitamin A that can lead to cancer cell differentiation, thereby slowing neuroblastoma cell growth and promoting neuroblastoma cell death (apoptosis). As a result, retinoic acid has become a common component of aggressive neuroblastoma treatment. The findings reported today showed that preclinical compounds from Acetylon’s HDAC1/2 inhibitor program exhibited a similar ability to induce cell death at therapeutically relevant concentrations, and that anti-cancer activity was ...

      Read Full Article
    19. TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors

      "KEYTRUDA and birinapant target different elements of cancer’s block against the immune system. TetraLogic’s birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system’s ability to kill abnormal cells via an extracellular TNF signal. Merck’s KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The proposed collaboration is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA."

      Read Full Article
    20. ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer

      ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer

      “We anticipate full patient enrollment in the ALTA trial in the third quarter of next year,” stated Frank G. Haluska, M.D., Ph.D., senior vice president of clinical research and development and chief medical officer at ARIAD. “Based on the continued responses seen in the ongoing Phase 1/2 trial of AP26113, and in particular, the 100% response rate and durability of response in the TKI-naïve patients,we are also actively planning a clinical trial to evaluate the potential of AP26113 in the newly diagnosed ALK+ lung cancer setting.” (In adults.)

      Read Full Article
      Mentions: ALK
    21. BSD Announces the Opening of the Center for Treatment of Children with Hyperthermia and Chemotherapy at Charité UMS

      SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Charité Universitätsmedizin Berlin (Charité), Department of Pediatric Hematology and Oncology, in cooperation with the Charité Department of Radiation Oncology, has opened a center dedicated to the treatment of pediatric tumors using hyperthermia and chemotherapy. Prof. Angelika Eggert MD, Chair of the Department of Pediatric Hematology and Oncology as well as President of th

      Read Full Article
      Mentions: Treatment
    22. Kolltan Cancer Study Results for KTN3379, Targeting ErbB3, Support Evaluating Combinations with Targeted Therapies

      NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs), today announced top-line results from the open-label, dose escalation monotherapy portion of its Phase 1 clinical trial program of KTN3379 in adult patients with advanced solid tumors. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB f

      Read Full Article
      Mentions: Antibody
    1-22 of 22
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video